- Filter by
- Categories
- Tags
- Show all
- Article
- Confusion
- Contract
- Copyright
- Corporate
- Domain Names
- Employment
- Expungement
- Expungement
- Grey Marketing
- Industrial Designs
- Licensing
- Obviousness
- Opposition
- Passing Off
- Patent
- Patent Infringement
- Patent Strategy
- PM(NOC)
- Procedure
- Prosecution
- recognition
- Services
- Summary
- Trade Secrets
- Trade-mark
- Use
- Validity
- 2019
- 35 US Code §101
- 3D printing
- 6.08
- Abandonment
- abstract
- abstract theorems
- accounting of profits
- acquired distinctiveness
- actions
- actual notice
- agreement
- agreements
- airport security
- Alice/Mayo Test
- Ambiguity
- Amending
- amendment
- Amendments
- annual maintenance fee
- Anticipation
- Appeal
- application
- application chain
- application fee
- arbitrary
- arbitration
- Assignment
- Australia
- Bad Faith
- bill
- Bill C-31
- Bill C-43
- Bill C-8
- Bill C-86
- biologics
- biosimilar
- Biotech Patents
- Blockchain
- border measures
- Brand
- branding
- broadcasting
- budget
- burden of proof
- business
- CAFC
- call processing
- Canada
- Canada Gazette
- Cannabis Law
- causal link
- cdrp
- CEEO
- Certificate of Supplementary Protection
- champerty
- Chemical Patent
- chemistry
- ciba
- CIPO
- CIPO errors
- CIRA
- Claim Construction
- Class Actions
- clerical error
- college of agents
- combination
- combination drugs
- commissioner
- Common General Knowledge
- Complete Code
- confidential
- Confidential Information
- confidentiality
- confidentiality order
- Conflict of Interest
- confusing
- confusingly similar
- confusion
- constitution
- constitutional
- constitutionality
- consumer goods
- contract
- contributory infringement
- Copyright
- Copyright Infringement
- copyright test
- corrections
- Costs
- counterfeit
- COVID-19
- CSP
- cybersecurity
- Damages
- Data
- Data Protection
- deadline
- deadlines
- defamation
- defences
- delay to market entry
- delayed market entry
- descriptive
- Design Patents
- deviation
- digital infringement
- disclosure
- distinctive
- distinctive feature
- distinctiveness
- Diversity
- division of powers
- divisionals
- DNA Patents
- domain
- domain names
- dominant feature
- dosage range
- Double Patenting
- doubtful cases
- due care
- E-Commerce
- Early dismissal
- economics
- errors
- essentiality of elements
- Ethics
- Europe
- Events
- Evidence
- examination quality
- examination statistics
- Examiner
- expert
- expert blinding
- expert evidence
- Experts
- expiry
- Expungement
- extraterritoriality
- federal circuit
- Federal Court
- Federal Court of Appeal
- fee
- fees
- file wrapper
- Filing
- filing date
- filing fee
- financial services
- foreign issue estoppel
- forum selection
- fraud
- Free World Trust
- frivolous
- funding
- future infringement
- generics
- geographical indications
- global
- Good Faith
- goods
- Government
- grace period
- grey marketing
- Hague
- hearsay
- hearsay evidence
- Honest Contractual Performance
- ICSID
- Illegality
- Improver
- imunity
- Indefiniteness
- Inducement
- Industrial Designs
- inherent distinctiveness
- injunction
- Injunctions
- Innovation
- insufficiency
- insufficient disclosure
- Intellectual Property
- intent
- Inter Partes Review
- interlocutory injunction
- Internet
- intra vires
- invalidated
- invalidation
- inventor removal
- inventorship
- IP Lawyer
- IP management
- ip regime
- IP Strategy
- IPIC
- IPO
- ISP
- IT patent
- ITC
- Jurisdiction
- Late fee
- Legal Retainer
- legal test
- legislative reform
- legitimate interest
- Licensing
- life science
- limitation periods
- Litigation
- litigation evidence
- litigation funding agreement
- madrid
- maintenance
- material facts
- materiality
- method
- Methods of Medical Treatment
- minister of health
- misleading
- monopoly
- motion
- Motion to dismiss
- Motion to strike
- NAFTA
- national phase entry
- new act
- new evidence
- no chance of success
- Non-Infringing Alternative
- notice of allegation
- notice to rectify
- novelty
- obivous error
- Obviousness
- Office
- official mark
- official marks
- on-sale
- on-sale bar
- Online
- ontario
- opposition
- outsourcing
- Overbreadth
- overlapping
- ownership
- Ownership & Inventorship
- PAB
- Passing Off
- patent abandonment
- Patent Act
- patent agent
- Patent Agents
- Patent and Trademark Appeal Board
- patent appeal board
- Patent Application
- Patent Drafting
- Patent Infringement
- Patent Litigation
- Patent Office
- patent office errors
- patent owner
- patent ownership
- patent practicioner
- patent prosecution
- patent protection
- patent requirement
- Patent Rules
- Patent Strategy
- patent term adjustment
- Patent Textbook
- Patent Trolls
- patentability
- Patentable Subject Matter
- Patents
- PCT
- Pharmaceutical Patent
- Pharmaceutical Pricing
- PLT
- PM(NOC)
- PM(NOC) Damages
- PMPRB
- POSITA
- price regulation
- pride
- prior art
- prior disclosure
- prior disclosure defence
- prior use
- priority
- priority claim
- priority claims
- priority date
- Privilege
- procedure
- Product Specificity
- profit
- prohibited marks
- Promise Doctrine
- proprietor
- Prosecution
- Prosecution History
- protective order
- prothonotaries
- Provisional Patent
- public sale
- Public Servant
- Punitive Damages
- Recognition
- Records
- registration
- reinstatement
- relevant date for construction
- Remedies
- representation
- request for correction
- requisition
- responding
- review
- risk
- Royalties
- s. 27
- s. 45
- s. 53
- sale
- Scheduling
- SCOTUS
- second person
- Secondary Infringement
- secondary meaning
- secret sale
- section 28
- Section 45
- section 50
- Section 52
- section 56
- section 7
- security
- selection patents
- Services
- settlement
- skilled person
- software
- Software Copyright
- Software Patent
- software patents
- Sound Prediction
- specification
- sponsorship
- SRED
- Standard of Review
- standing
- standing to appeal
- Start-up
- Startups
- statute of monopolies
- stay
- Strategy
- Sufficiency
- Summary Judgment
- summary trial
- superior court
- Supreme Court of Canada
- surname
- Technology
- Telecommunications
- test
- third party
- time frame
- top patent agent
- TPP
- Trade Secrets
- Trade-Mark
- trade-marks act
- Trademark
- Trademark Act
- trademark agent
- Trademark Infringement
- trademark opposition
- Trademarks use
- treaty
- UK
- united kingdom
- United States
- unpatentable
- untrue material allegation
- Use
- useful article
- USMCA
- USPTO
- Utility
- Validity
- variant
- Varying records
- Velocity
- vexatious
- who's who legal
July 5, 2017
July 5, 2017
2016 FC 525 - The Federal Court granted Celltrion’s motion to strike Janssen’s application pursuant to section 6(5)(b) of the PM(NOC) Regulations.
June 13, 2017
June 13, 2017
2016 FC 382 - The FC concluded that Apotex’s allegations of non-infringement in respect of Shire's Canadian Patent were justified and accordingly denied Shire’s requested prohibition order.
June 6, 2017
June 6, 2017
2016 FC 344 - Apotex alleged in its Notice of Allegation and submissions that the ‘632 Patent was invalid because it was obvious and lacked utility. The FC found that the allegation was justified.
May 9, 2017
May 9, 2017
2017 ONSC 224 - Apotex sought compensation from Eli Lilly for damages suffered for delayed entry to the market for its generic version of olanzapine; the ONSC ordered Eli Lilly to pay Apotex a total of $20,000.
May 2, 2017
May 2, 2017
2017 FCA 9 - The FCA affirmed the FC decision that AstraZeneca’s patent was valid and infringed, accepted Apotex’s appeal with respects to limitation periods, and rejected AstraZeneca’s cross-appeal regarding punitive damages.
March 14, 2017
March 14, 2017
2015 FC 1237 - The FC heard and granted an application by Leo Pharma to prohibit Teva Canada from being issued a Notice of Compliance under the PM(NOC) Regulations.
February 7, 2017
February 7, 2017
2016 FC 336 - The FC affirmed Prothonotary Tabib’s decision to strike some of Gilead Science's pleadings and allow the infringement action to continue on the basis of amended allegations of a likely future (quia timet) infringement.
February 3, 2017
February 3, 2017
2016 ONSC 7193 - The ONSC heard pleadings by Apotex and Pfizer concerning Pfizer’s, now invalid, patent for Viagra. Apotex had previously been prevented from manufacturing its own generic because of the Viagra patent, and now claimed damages for the delay in being able to market its own variant. The appeal was dismissed and Apotex’s claim was allowed to proceed unstruck.
January 3, 2017
January 3, 2017
2015 FC 1016 - In this decision, the FC permitted the applicant to proceed with its prohibition application, despite a previous decision finding that the patent in question was invalid.
October 21, 2016
October 21, 2016
2016 FCA 119 - The FCA dismissed the appeal, which alleged that Canadian Patent No. 2,226,784 was invalid on the basis of obviousness-type double-patenting and for lack of utility due to no sound prediction. As a result, the ‘784 patent was upheld.